Reports
Sale
Global Opioid Induced Constipation Market Share, Forecast: By Product: Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others; By Prescription Type: Over the Counter, Prescription; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Opioid Induced Constipation Market Outlook
The global opioid induced constipation market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by the rising prevalence of diseases and the rising cases of accidents.
Opioid Induced Constipation: Introduction
Opioids, sometimes called narcotics, are medications prescribed by doctors to treat persistent or severe pain. They are used by people with chronic headaches and backaches, by patients recovering from surgery or experiencing severe pain associated with cancer, and by adults and children who have gotten hurt playing sports or who have been seriously injured in falls, auto accidents, or other incidents. The central nervous system oversees how the body responds to pain. It also controls involuntary movements, including those of the digestive tract.
Medications which contain substances like morphine, codeine, oxycodone, and methadone are highly capable of causing opioid induced constipation. Common symptoms may include abdominal tenderness, bloating, distention, difficulty defecating, nausea, and vomiting, tiredness and lethargy, and weight loss, among others. Along with the use of medications, some health habits may also help relieve the condition, such as drinking more fluid, consuming more fibre, and getting some exercise.
Global Opioid Induced Constipation Market Analysis
The increasing number of randomized clinical trials to try new and effective treatments for opioid induced constipation are driving the market growth. For example, a randomized trial that took place in China used electroacupuncture for the treatment of opioid induced constipation and found it effective. Results showed improved bowel movement in patients with opioid induced constipation with rare adverse side effects. The increasing research and development for new drugs and therapies to treat chronic diseases, such as cancer, are directly aiding the global opioid induced constipation market share. Key players in the market are also increasing their focus on developing new drugs such as naldemedine and naloxegol, that may help resolve the issue for the patients, some of them being in clinical trials already, further anticipating the market expansion.
Apart from all this, there has been a significant shift towards non-pharmacological solutions to overcome opioid induced constipation. Such as dietary changes, proper hydration, and following an active lifestyle in combination with some regular exercises which may restrict the market growth a bit. The increasing investments by pharmaceutical companies in research and development activities towards producing targeted solutions for opioid induces constipation is also a major trend influencing the opioid induced constipation market growth.
Global Opioid Induced Constipation Market Segmentation
Market Breakup by Product
- Mu-opioid Receptor Antagonists
- Chloride Channel-2 Activators
- Others
Market Breakup by Prescription Type
- Over-the-Counter
- Prescription
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Opioid Induced Constipation Market Overview
The market for opioid induced constipation has been experiencing a significant boost in the market driven by the increasing prevalence of cancer worldwide. The boost in the market is also driven by the increasing geriatric population globally, which gets more susceptible to several chronic diseases with increasing age such as cancer, chronic backaches, and headaches, among others. The medications that are prescribed by doctors to treat such conditions contain opioid analgesics such as morphine, hydromorphone, and codeine, among others for chronic non-cancer pain with severe adverse effects on the digestive system. The rise in such conditions is the major factor increasing the demand for opioid induced drugs, propelling the market growth. The use of opioid analgesic prescriptions will increase with the growing geriatric population, further escalating the global opioid induced constipation market growth.
North America is expected to dominate the overall opioid-induced constipation market throughout the forecast period. This is due to the rising prevalence of various gastrointestinal disorders among geriatric patients in the region and a steep rise in the consumption of opioids in recent years. Cancer is a major public health problem worldwide and is the second leading cause of death in the United States. In 2024, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States.
Opioid Induced Constipation Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Fresenius Kabi AG
- Hikma Pharmaceuticals PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- GSK Plc.
- Bayer AG
- Aurobindo Pharma
- S.L.A. Pharma AG
- Salix Pharmaceuticals
- Takeda Pharmaceutical Company Limited
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Opioid Induced Constipation Market Overview
3.1 Global Opioid Induced Constipation Market Historical Value (2017-2023)
3.2 Global Opioid Induced Constipation Market Forecast Value (2024-2032)
4 Global Opioid Induced Constipation Market Landscape
4.1 Global Opioid Induced Constipation Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Opioid Induced Constipation Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Prescription Type
5 Global Opioid Induced Constipation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Opioid Induced Constipation Market Segmentation
6.1 Global Opioid Induced Constipation Market by Product
6.1.1 Market Overview
6.1.2 Mu-opioid Receptor Antagonists
6.1.3 Chloride Channel-2 Activators
6.1.4 Others
6.2 Global Opioid Induced Constipation Market by Prescription Type
6.2.1 Market Overview
6.2.2 Over the Counter
6.2.3 Prescription
6.3 Global Opioid Induced Constipation Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.3.5 Others
6.4 Global Opioid Induced Constipation Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Opioid Induced Constipation Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Opioid Induced Constipation Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Opioid Induced Constipation Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Opioid Induced Constipation Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Opioid Induced Constipation Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Mylan N.V.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Fresenius Kabi AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Hikma Pharmaceuticals PLC
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Teva Pharmaceutical Industries Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Bristol Myers Squibb Company
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 GSK Plc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Bayer AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Aurobindo Pharma
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 S.L.A. Pharma AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Salix Pharmaceuticals
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Takeda Pharmaceutical Company Limited
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
18 Global Opioid Induced Constipation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032.
The increasing prevalence of cancer globally is increasing the usage of medications containing substances, such as morphine, codeine, oxycodone, and methadone that cause OIC, are the major factors driving the market growth.
The increasing research and development activities to create targeted medications to overcome this medical condition is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
About 51-87% of patients receiving opioids for cancer suffer from opioid induced constipation.
The products available in the market include mu-opioid receptor antagonists and chloride channel-2 activators, among others.
These prescriptions include over the counter and prescriptions.
The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Key players involved in the market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc., Bayer AG, Aurobindo Pharma, S.L.A. Pharma AG, Salix Pharmaceuticals, and Takeda Pharmaceutical Company Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER